ESPAC-4: a multicenter, international, randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (gem) and capecitabine (cap), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.
Authors
Neoptolemos, JPalmer, D
Ghaneh, P
Valle, Juan W
Cunningham, D
Wadsley, J
Meyer, T
Anthoney, A
Glimelius, B
Falk, S
Lind, P
Izbicki, J
Middleton, G
Ross, P
Wasan, H
McDonald, A
Crosby, T
Psarelli, E
Hammel, P
Buechler, M
Affiliation
University of Liverpool, LiverpoolIssue Date
2016